State of Wyoming Invests $526,000 in Xenon Pharmaceuticals Inc. $XENE

State of Wyoming bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 8,710 shares of the biopharmaceutical company’s stock, valued at approximately $526,000.

Other institutional investors have also made changes to their positions in the company. Holocene Advisors LP bought a new position in Xenon Pharmaceuticals during the second quarter worth $56,637,000. Wellington Management Group LLP increased its holdings in shares of Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Xenon Pharmaceuticals by 1,968.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after purchasing an additional 820,608 shares during the period. Vestal Point Capital LP raised its position in shares of Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after purchasing an additional 700,000 shares during the period. Finally, Commodore Capital LP lifted its stake in shares of Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after buying an additional 700,000 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

XENE has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. HC Wainwright reissued a “buy” rating and issued a $74.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Royal Bank Of Canada decreased their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Finally, Needham & Company LLC lowered their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $77.13.

Insider Buying and Selling

In other news, Director Steven Gannon sold 10,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total value of $640,600.00. Following the completion of the transaction, the director owned 1,870 shares of the company’s stock, valued at approximately $119,792.20. This represents a 84.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,512 shares of company stock worth $774,088 in the last ninety days. 2.91% of the stock is owned by insiders.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $62.36 on Tuesday. Xenon Pharmaceuticals Inc. has a 1 year low of $35.60 and a 1 year high of $72.66. The stock has a market capitalization of $6.03 billion, a price-to-earnings ratio of -13.16 and a beta of 0.62. The company’s 50 day simple moving average is $61.57 and its 200 day simple moving average is $55.22.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same period in the prior year, the firm earned ($1.07) EPS. As a group, analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.